View Item 

Show simple item record

Pharmacologic and Bacteriologic Properties of SCH‐27899 (Ziracin), an Investigational Antibiotic from the Everninomicin Family
dc.contributor.authorFoster, David R.en_US
dc.contributor.authorRybak, Michael J.en_US
dc.date.accessioned2012-03-16T16:00:47Z
dc.date.available2012-03-16T16:00:47Z
dc.date.issued1999-10en_US
dc.identifier.citationFoster, David R.; Rybak, Michael J. (1999). "Pharmacologic and Bacteriologic Properties of SCH‐27899 (Ziracin), an Investigational Antibiotic from the Everninomicin Family." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19(10). <http://hdl.handle.net/2027.42/90360>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90360
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titlePharmacologic and Bacteriologic Properties of SCH‐27899 (Ziracin), an Investigational Antibiotic from the Everninomicin Familyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationotherAnti‐Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital/University Health Center Detroit, Michiganen_US
dc.contributor.affiliationotherDepartment of Internal Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University.en_US
dc.contributor.affiliationotherDepartment of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University.en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90360/1/phco.19.15.1111.30576.pdf
dc.identifier.doi10.1592/phco.19.15.1111.30576en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceBrieland JK, Loebenberg D., Menzel F., Cacciapuoti A., Hare R.. Efficacy of Ziracin (SCH27899), a new everninomicin antibiotic, against a replicative Legionella pneumophila lung infection in mice [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceIkejima H., Yamamoto H., Kunishima H., et al. In vitro activity of SCH27899 (Everninomicin, Ziracin) and seven other antimicrobial agents against Mycoplasma pneumoniae [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceRoblin PM, Reznik T., Kutlin A., Hammerschlag MR. In vitro activity of Ziracin (SCH‐27899) against Chlamydia pneumoniae and C. trachomatis [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceFuchs PC, Barry AL, Brown SD. In vitro activity of Ziracin (SCH27899) alone and in combination with other antimicrobial agents [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceJones RN, Barrett MS. Antimicrobial activity of SCH 27899 (Ziracin), oligosaccharide member of the everninomicin class with a wide gram‐positive spectrum. J Clin Microbiol Infect 1995; 1: 35 – 43.en_US
dc.identifier.citedreferenceCormican MG, Marshall SA, Jones RN. Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents. Diagn Microbiol Infect Dis 1995; 23: 157 – 60.en_US
dc.identifier.citedreferenceSchering‐Plough Research Institute. Data on file. Kenilworth, NJ.en_US
dc.identifier.citedreferenceBanfield C., Pai S., Swan SK, Lambrecht L., Laughlin M., Affrime M.. Effect of renal insufficiency in the single‐dose pharmacokinetics (PK) of SCH 27899 (Ziracin) [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceBlack J., Calesnick B., Falco FG, Weinstein MJ. Pharmacological properties of everninomicin D. Antimicrob Agents Chemother 1964; 4: 38 – 46.en_US
dc.identifier.citedreferenceBauernfeind A., Eberlein E., Jungwirth R.. Comparative bactericidal kinetics of SCH 27899 (Ziracin) at various dosages in a pharmacodynamic model [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario, Canada, September 28—October 1, 1997. Washington, DC: American Society for Microbiology, 1997.en_US
dc.identifier.citedreferenceWang E., Bergeron Y., Simard M., Cote‐Richer M., Bergeron MG. Efficacy of Ziracin (SCH 27899) in a mouse model of pneumococcal pneumonia [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceTomono K., Tomiyama Y., Hirakata Y., Maesaki S., Tashiro K., Kohno S.. In vivo activities of SCH 27899 (Ziracin) in a murine model of hematogenous pulmonary infection induced by Staphylococcus aureus enmeshed in agar bead. [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceTsitsi JML, Calver AD, Luke B., et al. A double‐blind, randomized, multicenter study of Ziracin versus ceftriaxone in patients with S. pneumoniae pneumonia [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferencePalmer SM, Rybak MJ. Vancomycin‐resistant enterococci. Pharmacotherapy 1996; 16: 819 – 29.en_US
dc.identifier.citedreferenceCormican MG, Jones RN. Emerging resistance to antimicrobial agents in gram positive bacteria: enterococci, staphylococci and nonpneumococcal streptococci. Drugs 1996; 51 ( suppl 1 ): 6 – 12.en_US
dc.identifier.citedreferenceJones RN, Sader HS, Erwin ME, Anderson SC. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 1998; 21: 85 – 93.en_US
dc.identifier.citedreferenceChant C., Rybak MJ. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 1995; 29: 1022 – 7.en_US
dc.identifier.citedreferenceAnonymous. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR 1997; 46: 813 – 15.en_US
dc.identifier.citedreferenceAppelbaum PC. Emerging resistance to antimicrobial agents in gram positive bacteria; pneumococci. Drugs 1996; 51 ( suppl 1 ): 1 – 5.en_US
dc.identifier.citedreferenceWeinstein MJ, Luedemann GM, Oden EM, Wagman GH. Everninomicin, a new antibiotic complex from Micromonospora carbonacea. Antimicrob Agents Chemother 1964; 4: 24 – 32.en_US
dc.identifier.citedreferenceSanders WE, Sanders CC. Microbiological characterization of everninomicins B and D. Antimicrob Agents Chemother 1974; 6: 232 – 8.en_US
dc.identifier.citedreferenceGanguly AK, Pramanik B., Cran TM, et al. The structure of new oligosaccharide antibiotics, 13‐384 components 1 and 5. Heterocycles 1989; 28: 83 – 8.en_US
dc.identifier.citedreferenceGanguly AK, Girijavallabhan VM, Miller GH, Sarre OZ. Chemical modifications of everninomicins. J Antibiot 1982; 35: 561 – 70.en_US
dc.identifier.citedreferenceBlack TA, Zhao W., Shaw KJ, Hare S.. Physiological investigation on the mechanism of action of SCH 27899 (Ziracin) [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy. San Diego, CA: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceAdrian PV, Klugman KP. Ribosomal protein L16: the putative target site for everninomicin (SCH 27899) action in Streptococcus pneumoniae [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceNakashio S., Iwasawa H., Dun FY, Kanemitsu K., Shimada J.. Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post‐antibiotic effect and synergistic bactericidal activity. Drugs Exp Clin Res 1995; 21: 7 – 16.en_US
dc.identifier.citedreferenceUrban C., Mariano N., Mosinka‐Snipas K., Wadee C., Chahrour T., Rajal J.. Comparative in vitro activity of SCH 27899, a novel everninomicin, and vancomycin. J Antimicrob Chemother 1996; 37: 361 – 4.en_US
dc.identifier.citedreferenceMurakami H., Hanaki H., Sasaki K., Inaba Y., Hori N., Hiramatsu K.. In vitro activity of everninomicin (EVNIM, Ziracin), a new injectable antibiotic, against clinically isolated strains including vancomycin low‐resistant Staphylococcus aureus and VRE [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceWilley BM, Sachse L., Mustachi B., McGeer A., Low DE. Comparative in vitro activities of a new oligosaccharide everninomicin (SCH27899) against clinical enterococci [abstr]. In: Abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, LA, September 15–18, 1996. Washington, DC: American Society for Microbiology, 1996.en_US
dc.identifier.citedreferenceManzor O., Saravolatz J.. In vitro activity of Ziracin (SCH27899), levofloxacin and three other quinolones against S pneumoniae [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceTakemura H., Ikejima H., Kunishima H., et al. Evaluation of antimicrobial activities of SCH27899 (everninomicin, Ziracin) for Legionella spp [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceEdelstein PH, Edelstein MAC, Ren J.. In vitro activity of SCH 27899 (Ziracin) against 104 Legionella spp [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferenceTanaka K., Kato N., Watanabe K.. In vitro activity of everninomicin‐derivative SCH27899 (Ziracin) and other agents against anaerobic bacteria [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.identifier.citedreferencePavia C., Wormser G., Nowakowski J., Caccaiputi A.. Comparative in vitro sensitivity of Borrelia burgdorferi to Ziracin (SCH27899), penicillin and ceftriaxone [abstr]. In: Abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24–27, 1998. Washington, DC: American Society for Microbiology, 1998.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.19.15.1111.30576.pdf
Size:
60.82KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.